Cost-effectiveness analyses of human papillomavirus vaccination (Q36765963)

16 August 2017

1 reference

title

Cost-effectiveness analyses of human papillomavirus vaccination (English)

1 reference

cost-effectiveness analysis

16 August 2017

main subject

1 reference

4

W John Edmunds

1 reference

16 August 2017

5

C Raina MacIntyre

1 reference

16 August 2017

Anthony T Newall

1

1 reference

16 August 2017

Philippe Beutels

series ordinal

2

1 reference

16 August 2017

James G Wood

series ordinal

3

1 reference

16 August 2017

publication date

1 April 2007

1 reference

Lancet Infectious Diseases

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

289-296

1 reference

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Epidemiologic Evidence and Human Papillomavirus Infection as a Necessary Cause of Cervical Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Epidemiology of Genital Human Papillomavirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Chapter 9: Role of mucosal human papillomavirus in nongenital cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Efficacy and other milestones for human papillomavirus vaccine introduction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

International trends in incidence of cervical cancer: II. Squamous-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

The health care costs of cervical human papillomavirus--related disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Cost-effectiveness of a potential vaccine for human papillomavirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Evaluating human papillomavirus vaccination programs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening*1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Economic evaluation of vaccination programs: the impact of herd-immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Health economic guidelines--similarities, differences and some implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Need for differential discounting of costs and health effects in cost effectiveness analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Vaccination against multiple HPV types

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Herd immunity: history, theory, practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Methodological issues and new developments in the economic evaluation of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Natural history of cervicovaginal papillomavirus infection in young women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970083-X

7 January 2021

10.1016/S1473-3099(07)70083-X

Identifiers

DOI

1 reference

16 August 2017

1 reference